WO2026037337 - METHODS FOR PREPARING CONJUGATED COMPOUNDS AND ANTIBODY-DRUG CONJUGATES
National phase entry is expected:
Publication Number
WO/2026/037337
Publication Date
19.02.2026
International Application No.
PCT/CN2025/114429
International Filing Date
13.08.2025
Title **
[English]
METHODS FOR PREPARING CONJUGATED COMPOUNDS AND ANTIBODY-DRUG CONJUGATES
[French]
PROCÉDÉS DE PRÉPARATION DE COMPOSÉS CONJUGUÉS ET CONJUGUÉS ANTICORPS-MÉDICAMENT
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
AN, Wenqian
HAN, Yanfei
ZHANG, Ziyang
CAO, Wenpeng
Priority Data
PCT/CN2024/111795
13.08.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3386 | |
| EPO | Filing, Examination, Granting | 38012 | |
| Japan | Filing, Examination, Granting | 3416 | |
| South Korea | Filing, Examination, Granting | 4747 | |
| USA | Filing, Examination, Granting | 15190 |
Total:
64,751
Contact Us
Abstract[English]
This disclosure relates to conjugated compounds and antibody-drug conjugates (ADCs) having a non-native cysteine residue for payload conjugation. Such conjugates may have a DAR of about 1, and can be used for diagnostic, scientific and therapeutic applications.[French]
La présente divulgation concerne des composés conjugués et des conjugués anticorps-médicament (ADC) ayant un résidu cystéine non natif pour une conjugaison de charge utile. De tels conjugués peuvent avoir un DAR d'environ 1, et peuvent être utilisés pour des applications diagnostiques, scientifiques et thérapeutiques.